Alistair Swanson

Alistair Swanson joined DNDi as Head of Product Development for HIV & Hepatitis C Initiative in January 2018. Since February 2022, Alistair is Head of Product Development for leishmaniasis and mycetoma (NTD Leishmaniasis-Mycetoma Cluster).

Alistair has a degree and doctorate in Chemistry and over 30 years’ experience in the Pharma industry, initially with Pfizer R&D then, for the last seven and a half years, as an independent consultant. In Pfizer, he held a variety of management and leadership positions, with a focus on new product development, registration, and portfolio management. He also led several large business integration and process change projects.

In addition to DNDi, he has worked as a consultant with a range of large and small R&D organisations in Pharma and other regulated industries to develop technical and regulatory strategies and implement effective project and portfolio management systems.